# Anjarium Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anjarium-biosciences

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.anjarium.com
- Total disclosed funding: $61M
- Latest round: Series A (Sep 15, 2021)
- Investors on record: 5

## About

Based in Zurich, Switzerland, and founded in 2017, Anjarium Biosciences AG provides a novel class of bioinspired nanomedicine. The company was founded by Joël de Beer and in September 2021, The company raised its latest Series A funding co-led by Abingworth and Gimv.

Anjarium Biosciences AG’s platform builds on novel therapeutic payloads and delivery technologies and also aims to unlock the full potential of gene therapy.

The company plans to use its 2021 Series A funding to expand its team, advance its platform, and progress several therapeutic pipeline programs towards clinical development.

## Funding rounds

- Series A, Sep 15, 2021, $61M — Abingworth, Gimv, Omega Funds, Pfizer Venture Investments, Surveyor Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Surveyor Capital — Series A